E-Cigarettes and Cardiopulmonary Health
Neczypor EW, Mears MJ, Ghosh A, et al. E-Cigarettes and Cardiopulmonary Health: Review for Clinicians. Circulation. 2022;145:219–232. “PubMed and the Cochrane Central Register of Controlled Trials were searched for English language studies related to e-cigarettes from January 2012 through November 2020…. This search resulted in 384 results which were screened by the authors.
https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.121.056777
Cardiovascular studies reported sympathetic activation, vascular stiffening, and endothelial dysfunction, which are associated with adverse cardiovascular events…. Associations were reported between e-cigarette use and higher incidence of asthma (OR range = 1.39–3.41 [95% CI range: 1.15–6.49]), respiratory disease (OR range = 1.31–2.58 [95% CI range: 1.03–4.89]), COVID-19 (OR = 5.05 [95% CI: 1.82–13.96]), wheeze (OR = 1.67 [95% CI: 1.23–2.15]), and myocardial infarction (OR = 1.79 [95% CI: 1.20–2.66]). Furthermore, dual use of e-cigarettes and cigarettes has been associated with higher rates of cardiovascular disease (OR = 1.36 [95% CI: 1.18–1.56]), and cardiovascular risk factors, including metabolic syndrome (OR = 1.57 [95% CI: 1.03–2.40]) versus sole cigarette users.”
Stephen Hamann
